Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Peking University Novartis |
---|---|
Information provided by: | Peking University |
ClinicalTrials.gov Identifier: | NCT00881049 |
This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and safety. The primary endpoint is progression-free survival (PFS) and the second endpoints are overall response rate (ORR), overall survival (OS), 1-year OS and safety.
Condition | Intervention | Phase |
---|---|---|
Metastatic Melanoma |
Drug: Imatinib (Gleevec) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Trial of Imatinib(Gleevec®) in Selected Patients With Metastatic Melanoma |
Estimated Enrollment: | 1 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | June 2011 |
Estimated Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
Only patients who meet the inclusion and exclusion criteria will be enrolled. The estimated recruitment duration is 1 year. Imatinib will be given in the dose of 400 mg orally each day unless disease progression or intolerance. The follow-up is 12 months. Forty-eight subjects will be recruited for this study. This sample size is justified by the number of patients required to establish an improvement in PFS with statistical significance compared to historical control.
The standardized RECIST (Response Evaluation Criteria in Solid Tumors) method of unidimensional tumor assessment will be employed to evaluate tumor lesion size per 2 months in the determination of response rate and progression free survival. Repeated radiographic assessment at 4 week intervals is consistent with general oncological practice associated with computerized tomography (CT) or magnetic resonance imaging (MRI) scan testing. All efficacy endpoints will be evaluated by the investigator.
Safety will be characterized in terms of the incidence, timing, severity, and relatedness of adverse events and laboratory abnormalities. Severity will be graded according to the NCI CTCAE Version 3.0.
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
China, Bejing | |
Beijing Cancer Hospital | Recruiting |
Beijing, Bejing, China, 10036 | |
Contact: Jun Guo, M.D. 010-88121122 Guoj307@126.com | |
Principal Investigator: Jun Guo, M.D. |
Responsible Party: | Beijing Cancer Hospital ( Jun Guo ) |
Study ID Numbers: | CSTI571BCN19T |
Study First Received: | April 13, 2009 |
Last Updated: | April 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00881049 History of Changes |
Health Authority: | China: State Food and Drug Administration |
metastatic acral or mucosal melanoma with c-kit mutation or copy number increase |
Imatinib Neuroectodermal Tumors Nevus, Pigmented Neoplasms, Germ Cell and Embryonal Neuroepithelioma |
Nevus Protein Kinase Inhibitors Neuroendocrine Tumors Melanoma |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Neoplasms, Nerve Tissue Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions Melanoma |
Neuroendocrine Tumors Imatinib Neuroectodermal Tumors Neoplasms Therapeutic Uses Neoplasms, Germ Cell and Embryonal Nevi and Melanomas |